Upload
maqsood-mehmood
View
872
Download
0
Embed Size (px)
DESCRIPTION
basic insulin regimens
Citation preview
In the Name of ALLAH, Ever Beneficent, Infinitely Merciful
04/11/2304/11/23 22
04/11/2304/11/23 33
04/11/23 4
HOW TO DIAGNOSEHOW TO DIAGNOSEDIABETES?DIABETES?
04/11/2304/11/23 55
TREATMENT TARGETSTREATMENT TARGETS
04/11/2304/11/23 66
Efficacy of Monotherapy in Type 2 Diabetes
Agent HbA1c reduction %
Fasting glucose
Reduction (mg/dl)
Sulphonylurea 1.5 - 2.0 60 - 80
Metformin 1.5 - 2.0 60 - 80
Pioglitazone 0.6 - 1.9 50 - 80
Alpha Gucosidase inhibitor
0.5 - 1.0 20 - 30
Bonnie Kimmel, MD and Silvio E. Inzucchi, MD Clinical Diabetes 23:64-76, 200504/11/2304/11/23 77
Current FDA Approved
Combination Therapy Options in Type 2 Combination Additional
Lowering of HbA1c
Additional Lowering of FBG
(mg/dl)
SU + MTF 1.5 – 2.0 60 – 80
SU + TZD 1.0 – 1.5 40 – 60
MTF + TZD 0.6 – 0.8 20 – 40
SU + AGI 1.0 – 1.5 20 – 40
Bonnie Kimmel, MD and Silvio E. Inzucchi, MD Clinical Diabetes 23:64-76, 2005
04/11/2304/11/23 88
Mazze, Strock, Simonson, Kendall, Cuddihy, Bergenstal. SDM Quick Guide 5th Edition, International Diabetes Center, 2009
Staged DiabetesManagement at IDC
*
04/11/2304/11/23 99
Stages of Type 2 Diabetes—Stages of Type 2 Diabetes—UKPDSUKPDS
-C
ell
Funct
ion (
%)
PostprandialHyperglycemia
IGT Type 2DiabetesPhase I Type 2
DiabetesPhase II
Type 2 DiabetesPhase III
25
100
75
0
50
-12 -10 -6 -2 0 2 6 10 14
Years From Diagnosis
Lebovitz H. Diabetes Review. 1999;7:139.04/11/2304/11/23 1010
04/11/2304/11/23 1111
04/11/2304/11/23 1212
Patient J.L., December 15, 1922 Februray 15, 1923
The Miracle of The Miracle of InsulinInsulin
04/11/23 13
Adapted from Stratton IM, et al. UKPDS 35. BMJ 2000; 321:405–412.
UKPDS: decreased risk of diabetes-related complications UKPDS: decreased risk of diabetes-related complications associated with a 1% decrease in A1Cassociated with a 1% decrease in A1C
UKPDS: decreased risk of diabetes-related complications UKPDS: decreased risk of diabetes-related complications associated with a 1% decrease in A1Cassociated with a 1% decrease in A1C
Per
cen
tag
e d
ecre
ase
in r
ela
tive
ris
k co
rres
po
nd
ing
to
a 1
% d
ecre
ase
in H
bA
1C
**
Any diabetes-related endpoint
21%
**
Diabetes-related death
21% **
All cause
mortality
14%*
Stroke
12%
**
Peripheral vascular disease†
43%
**
Myocardial infarction
14%
**
Micro-vascular disease
37%
**
Cataract extraction
19%
Observational analysis from UKPDS study data
†Lower extremity amputation or fatal peripheral vascular disease*P = 0.035; **P < 0.0001
04/11/2304/11/23
1414
“The Magnificent Seven”
When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus?Type 2 diabetes mellitus?
04/11/2304/11/23 1616
1. Type 2 diabetes not controlled with maximal doses of Oral Hypoglycaemic agents
What do you mean by maximal doses of OHAs?
Metformin 2500/3000mg a day
+
Glipizide 20mg/glibenclemide15-20mg/day
Gliciazide 320mg/ Glimepride 6-8mg/day
+
Rosiglitazone 8mg/ Pioglitazone 45mg/day
When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus?Type 2 diabetes mellitus?
04/11/2304/11/23 1717
2. Type 2 diabetes during periods of physiological
stress (surgery, infection)
Continue OHAs simultaneously.
Stop metformin in case of severe infections or
impending reduction in renal perfusion
When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus?Type 2 diabetes mellitus?
04/11/2304/11/23 1818
04/11/2304/11/23 1919
04/11/2304/11/23 2020
04/11/2304/11/23 2121
3. gestational diabetes
Metformin may be continued
Discontinue other medications
When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus?Type 2 diabetes mellitus?
04/11/2304/11/23 2222
04/11/2304/11/23 2323
4. Use of parenteral nutrition
or high-caloric supplements
Indications of Insulin therapy?Indications of Insulin therapy?
04/11/2304/11/23 2424
5. Diabetic ketoacidosis (DKA)/Hyperosmolar
hyperglycemic nonketotic syndrome (HHNS)
Indications of Insulin therapy?Indications of Insulin therapy?
04/11/2304/11/23 2525
6. Progressive complications:
proliferative retinopathy/maculopathy, progressive or painful neuropathy
For rapid control and tighter adjustment
Indications of Insulin therapy?Indications of Insulin therapy?
04/11/2304/11/23 2626
7. Chronic Renal Failure
For all above a creatinine of 4.0mg/dl
Cutoffs for other OHAs:-
Metformin: 1.5mg/dl
Glimeperide/Glibenclemide: 2.0mg/dl
Glipizide: 2.5mg/dl
Pioglitazone/Rosiglitazone: 4.0mg/dl
Indications of Insulin therapy?Indications of Insulin therapy?
04/11/2304/11/23 2727
Normal PancreasNormal Pancreas
Insulin is released in response to varying blood glucose levels and hypoglycemia does not occur
Insu
lin E
ffec
t
Basal Insulin (~0.5-1.0 U/hr)
‘Bolus’ Insulin (Meal Associated)
04/11/2304/11/23 2828
How does one classify the types of insulin?How does one classify the types of insulin?
Generally classified according to peak effect and duration of action
Rapid acting/lispro /aspart/glulisine
Short acting: regular.
Intermediate acting: NPH.
Long acting(basal) lantus. /levimer.
Premixed:(30/70), (50/50), (75/25)04/11/2304/11/23 2929
Re
lati
ve
Ins
ulin
Eff
ec
tR
ela
tiv
e In
su
lin E
ffe
ct
Time (Hours)
0 2 4 6 8 10 12 14 16
Long-Acting: Glargine (Lantus®)Detemir (Levemir®)
18 20
Intermediate: NPH (Humulin® N, Novolin® N)
Short-Acting: Regular (Humulin® R, Novolin® R)
Rapid-Acting: Lispro (Humalog®), Aspart (NovoLog®),Glulisine (Apidra®)
Insulin Time Action Curves
Bergenstal, “Effective insulin therapy,” International Textbook of Diabetes Mellitus vol 1. 3rd ed, Chichester NY, John Wiley and Sons, Inc., 2004:995-1015. 04/11/23 31
What are the types What are the types of insulin regimens?of insulin regimens?
• Premixed regimen
• Split mix regimen
• Basal bolus regime (multidose)
• Bedtime dosing alone (NPH/Lente/Glargine)
• Infusion
04/11/2304/11/23 3232
Premixed insulinPremixed insulinAVAILABLE PREPRATIONSAVAILABLE PREPRATIONS • Premixed(30/70): Regular: 30 % NPH :
70%
• Premixed (50/50): lispro 50% NPL 50%
• Premixed Analogs Biphasic insulin aspart (30/70) 30% : Aspart 70% : protaminated aspart
04/11/2304/11/23 3333
04/11/2304/11/23 3434
04/11/2304/11/23 3535
04/11/23 36
Basic Insulin Regimen: Basic Insulin Regimen: Split-Mixed Regimen or Split-Mixed Regimen or
PremixPremix
Regular
NPH
B DL HS B
Endogenous insulin
04/11/2304/11/23 3737
Basic Insulin Regimen: Basic Insulin Regimen: Split-Mixed Regimen or Split-Mixed Regimen or
PremixPremix• Does not
mimic normal physiology
• Requires meal consistency
• Snacking may result in weight gain
• Hypo- and hyperglycemia
Regular
NPH
B DL HS B
Endogenous insulin
Hyperglycemia
04/11/2304/11/23 3838
Insulin Therapy RegimensInsulin Therapy Regimens
Usual starting dose: 0.5-1.0 unit/kg/day
04/11/2304/11/23 3939
Premixed insulinPremixed insulin
• Dose adjustment:
• The fasting sugar depends on the night dose of insulin • The post breakfast sugar depends on the
morning dose of insulin
• Rough calculation increase the insulin by one unit to reduce the sugars by 25mg/dl
04/11/2304/11/23 4040
Self Monitoring is crucialSelf Monitoring is crucial
Glucometers
At least 6-8 times a week ideally
04/11/2304/11/23 4141
Premixed insulinPremixed insulin Advantages • more accurate dosing
• lesser injections
• Pen devices administer premixed forms
Disadvantages • Fine tuning may not be possible
• Strict meal pattern
• Nocturnal hypoglycemia
• May need “diet changes for insulin” rather than “insulin changes for diet”
04/11/2304/11/23 4242
TIMING OF INJECTIONTIMING OF INJECTION
• 70/30 30 MINUTES BEFORE BREAKFAST AND SUPPER
• NOVO MIX 70/30
• HUMALOG MIX 25/75 5—15 MINUTES
• BEFORE BREAKFAST AND SUPPER
04/11/2304/11/23 4444
ADVANTAGESADVANTAGES
• SIMPLE AND EASY TO USE ;draw A SINGLE DOSE OF A COMBINATION OF INSULIN IN ONE SYRINGE
• MINIMUM INSULIN DOSING THAT PROVIDES 24-HOUR INSULIN COVERAGE
• HUMALOG MIX 75/25 INSULIN OR NOVO MIX 70/30 INSULIN CAN BE TAKEN 5-15 MINUTES BEFORE A MEAL
04/11/2304/11/23 4545
DISADVANTAGESDISADVANTAGES
• 70/30 INSULIN ;SHOULD WAIT 30 MINUTES AFTER INSULIN INJECTION BEFORE EATING THE MEAL
• FIXED RATIO OF INTERMEDIATE AND SHORT OR RAPID ACTING INSULIN MAY NOT CONTROL BLOOD GLUCOSE LEVELS
• CAN NOT ADJUST INTERMEDIATE-ACTING INSULIN COMPONENT WITHOUT ADJUSTING THE SHORT OR RAPID ACTING INSULIN COMPONENT
04/11/2304/11/23 4646
DISADVANTAGESDISADVANTAGES
• CAN NOT ADJUST REGULAR INSULIN,INSULINASPART, OR INSULIN LISPRO FOR VARIATION IN FOOD INTAKE, BLOOD GLUCOSE LEVELS OR EXERCISE
• MUST TAKE INSULIN AND EAT MEALS ABOUT THE SAME TIME EVERY DAY MUST EAT ACONSISTANT AMOUNT OF CARBOHYDRATES AT EACH MEAL FROM DAY TO DAY
• LEAST FLEXABLE OF ALL REGIMENS
04/11/2304/11/23 4747
INDICATIONSINDICATIONS
• PATIENTS WITH LIMITED CAPABILITIES
• PATIENTS WHO ARE UNWILLING TO INTENSIFY REGIMEN
• INITIAL REGIMEN AFTER DIAGNOSES TO LEARN AND ADAPT TO INJECTIONS
• TYPE 2 DIABETES04/11/2304/11/23 4848
04/11/2304/11/23 4949
STARTING DOSESTARTING DOSE
• 2/3 TOTAL DAILY DOSE BEFORE BREAKFAST ,1/3 TOTAL DAILY DOSE BEFORE SUPPER
• 0.5—1.0 U/KG/DAY
04/11/2304/11/23 5050
Pre-mix (Pre-mix (70/3070/30))• Gaps in insulin coverage
• Poor long-term control
• Failure to match endogenous secretion pattern
• Dawn phenomenon
• Increased glycaemia
04/11/2304/11/23 5151
Can Oral hypoglycaemic agents
be continued at the same time with insulin?
• Metformin Best continued if renal function is normal. May
reduce insulin requirements by 15-30%.• Adjunctive weight reducing effect
• Thiazolidinediones • May be continued with insulin. • Can reduce insulin requirements from 15-60% • Major issue of weight gain, accentuated by
insulin: 7.5%. 15%>5kg.
04/11/2304/11/23 5252
Can Oral hypoglycaemic agents
be continued at the same time with insulin?
• Sulphonylureas
• Glimeperide: doses of 2-4mg a day have a peripheral GLUT-4 activity reducing insulin requirement by 10-20%.
• Glipizide and Glibenclemide can reduce insulin requirements by 5-15%.
• Unpredictable- recommended previously in those with high C-peptide levels
04/11/2304/11/23 5353
Insulin administration is suitably as premixed fashion for Insulin administration is suitably as premixed fashion for most type 2 diabetes. Split-mix may be required in a most type 2 diabetes. Split-mix may be required in a subset. subset.
The neccessity of self blood glucose monitoring as a The neccessity of self blood glucose monitoring as a accessory is emphasized. accessory is emphasized.
Summarizing……..Summarizing……..
04/11/2304/11/23 5454
Aggressively Titrated Premix
70/30+Met+Pio Met+Pio
Baseline A1C 8.1±1.0 7.9±0.9
EOS A1C 6.5±1.0 7.8±1.2
Percentage of Patients With A1C (EOS)
<7.0% 76.3 24.1
≤6.5 59.1 11.5
≤6.0 33.3 2.3
≤5.5 14.0 0
FPG (mg/dl) 130±50 162±41
Raskin et al. Insulin 2007;2 (suppl A):S1104/11/23 55
Comparison of Common Insulin Regimens*
Variable Glargine* NPH1 Premix2,3 Detemir4
Efficacy Insulin Works
Hypoglycemia† 1.0 1.4X 2.5-5.0X 1.0
Insulin Dose 1.0 1.0 1.5-2.0X 1.6-2.1X
Weight Gain 1.0 1.0 1.5X 0.7-1.0X
*Normalized to glargine; sponsored comparator trials †Confirmed hypoglycemia1Riddle MC et al. Diabetes Care 2003;26:3080-3086 2Janka HU et al. Diabetes Care 2005;28:254-259 3Raskin P et al. Diabetes Care 2005;28:260-265 4Rosenstock J et al. ADA 2006; Abstract 555-P
04/11/23
56
Tuesday, April 11, 2023
57
04/11/2304/11/23 5858
04/11/2304/11/23 DR MAXUD DIABETOLOGISTDR MAXUD DIABETOLOGIST 5959
04/11/23 60
04/11/23
61